Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL Of Australia Considers Doubling Seasonal Flu Vaccine Production

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL is considering production of twice the seasonal influenza vaccine it had planned for the next fiscal year. The company decided on the move after U.S. pre-season orders reserved nearly all of the production originally planned. In demand is CSL's Afluria, expected to be worth $80 million in sales in the year that begins July 1. The U.S. military is expected to be a major buyer of the batch of 9 million doses exported by CSL. A market analyst said the U.S. order might be driven by the increased flu awareness brought on by the H1N1 pandemic. (Click here for more

You may also be interested in...

First Out Of The Gate, CSL Begins Adult Trials Of H1N1 Flu Vaccine

PERTH, Australia - Melbourne-headquartered CSL Limited will begin clinical trials of its H1N1 influenza vaccine in healthy adults ages 18 to 64 July 22, and pediatric trials will commence Aug. 1, CSL said

COVID-19 Could Drive UK OTC Rises

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.

Sandoz Keeps Tabs On Teva Skinny Label Ruling

As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts